Sasso, CorinaSantiano, FlaviaLópez-Fontana, ConstanzaPistone-Creydt, VirginiaEzquer, MarceloHapon, MaríaJahn, GracielaCarón, Rubén2017-03-132017-03-132014Biomed Res Int. 2014; 2014: 210424http://hdl.handle.net/11447/1018http://dx.doi.org/10.1155/2014/210424Centro de Medicina RegenerativaProlactin (PRL) is a key player in the development of mammary cancer. We studied the effects of parity or hyperprolactinemia on mammary carcinogenesis in OFA hr/hr treated with 7,12-dimethylbenzanthracene. They were divided into three groups: nulliparous (Null), primiparous (PL, after pregnancy and lactation), and hyperprolactinemic rats (I, implanted in the arcuate nucleus with 17β-estradiol). The tumor incidence was similar in the three groups. However, a higher percentage of regressing tumors was evident in the PL group. Serum PRL, mammary development, and mammary β-casein content were higher in I rats compared to Null. The expression of hormone receptors was similar in the different groups. However, mammary tissue from PL rats bearing tumors had increased expression of PRL and estrogen alpha receptors compared to rats free of tumors. Our results suggest that serum PRL levels do not have relevance on the incidence of tumors, probably because the low levels of PRL in OFA rats are not further decreased by PL like in other strains. However, supraphysiological levels of PRL affect carcinogenesis. PL induces regression of the tumors due to the differentiation produced on the mammary cells. Alterations in the expression of hormonal receptors may be involved in progression and regression of tumors.11en-US9,10-Dimethyl-1,2-benzanthracene/toxicityAnimalsCarcinogens/toxicityMammary Glands, Animal/pathologyProlactin/bloodRatsArtículo